A research filter, not a predictor — not financial advice. Grades rank growth stocks on evidence-based quality signals from end-of-day data; they are not buy/sell calls or price forecasts. Always do your own research.
Caris Life Sciences, Inc. CAI
Promising (early) broader-coverage candidate · Caris Life Sciences, Inc.
On FrontierLab's discovery record since 2026-06-15 (9 weeks ago) — when this name first surfaced. (distinct from the snapshot date below)
Auto-graded broader coverage — sourced by an automated screen and graded on default bands, not the sector-calibrated bands the curated screener uses. A "Promising (early)" here is NOT the same bar as a curated grade; these are auto-screened candidates for your own research, shown as of their surface date (2026-07-24), not the curated Frontier signal.
Key quality signals
| Revenue growth (YoY) | 125.4% |
|---|---|
| Gross margin | 68.7% |
| Gross profits / assets | 0.54 |
| Rule of 40 | 141.3 |
| Net margin | 15.9% |
| Cash runway (months) | — |
| PEG | — |
| Price / sales | 4.9 |
Quality checklist
- ✓ Revenue growth — 125.4% (pass ≥ 20%)
- ✓ Capital efficiency
- ✓ Gross margin — 68.7% (pass ≥ 60%)
- ✓ Gross-margin trend — 25.3 (pass ≥ 2)
- ~ Share dilution — 10.9%
Fundamentals — snapshot as of 2026-07-24
| Stage | Early |
|---|---|
| Share issuance (YoY) | 10.9% · heavy issuance |
| Moat | — |
| TAM | — |
| P/E (trailing) | — |
| EPS (trailing) | $-1.51 |
| Burn multiple | — |
| Gross-margin trend (pts) | 25.3 |
| Cash / assets | 0.71 |
| Net debt / EBITDA | -3.5 |
| Statements as of | Q1 FY2026 · filed 2026-05-08 |
Momentum context — a snapshot from 2026-07-24, not current
| Price at surface | $15.65 (as of 2026-07-24) |
|---|---|
| 52-week range | $14.19 – $42.5 |
| % off 52-wk high | -63.2% |
| RSI (14) | 39 |
| Relative volume | 0.7× |
Risk flags
← All broader-coverage names · Curated names → · Open the interactive screener →
Data as of 2026-07-24 (end-of-day). How grades are computed →